Regulation Catches Up to Reality
- PMID: 27630249
- PMCID: PMC5375077
- DOI: 10.1177/1932296816667749
Regulation Catches Up to Reality
Abstract
The FDA recently conducted an Advisory Panel meeting to evaluate the safety, efficacy, and benefits of granting a nonadjunctive label claim for the DEXCOM G5 Mobile continuous glucose monitoring (CGM) system. If approved, this claim will allow users to make day-to-day treatment decisions, including insulin dosing directly from the glucose values and rate of changes arrows generated by the CGM device, without the requirement of a confirmatory measurement with a self-monitoring blood glucose (SMBG) meter. Sporadic SMBG testing gives limited data, while CGM gives a value every 5 minutes and has alerts, alarms, trending information and allows caregivers to follow the user in real time 24/7. This indication will lead to more wide spread use of CGM and improve overall care with protection of hypoglycemia.
Keywords: CGM; FDA panel meeting; SMBG; nonadjunctive claim.
Conflict of interest statement
Figures
References
-
- Food and Drug Administration. Advisory committees. Available at: http://www.fda.gov/AdvisoryCommittees/default.htm. Accessed August 12, 2016.
-
- Beck RW, Tamborlane WV, Bergenstal RM, et al. The T1D Exchange Clinic Registry. J Clin Endocrinol Metab. 2012;97:4383-4389. - PubMed
-
- Pettus J, Price DA, Hill KJ, Edelman S. How people use direction and rate of change information provided by real-time continuous glucose monitoring (RT-CGM) to adjust insulin dosing. Diabetes Technol Ther. 2014;16(S1):198. - PubMed
-
- Pettus JH, Hirsch IB, Edelman SV. Practical Management of Type 1 Diabetes. 2nd ed. Greenwich, CT: Professional Communications; 2013.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
